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INTRODUCTION 
Studies of adaptive immunity to SARS-CoV-2 include 
characterization of lethal, severe and mild cases (1–8). Under-
standing how long immunity lasts in people who have had 
mild or asymptomatic infection is crucial. Healthcare worker 
(HCW) cohorts exposed to and infected by SARS-CoV-2 dur-
ing the early stages of the pandemic are an invaluable re-
source to study this question (9–14). The UK COVIDsortium 
is a longitudinal, London hospital HCW cohort, followed 
from the time of UK lockdown on 23rd March 2020 (9, 10); 
weekly nasopharyngeal swabs for SARS-CoV-2 polymerase 
chain reaction (PCR), serology and serum collection for anti-
body analysis and a self-reporting health questionnaire al-
lowed capture of mild/asymptomatic infection around the 
time of onset, so duration of immunity could be tracked. The 
majority of healthy people infected in the community with 
SARS-CoV-2 have not been hospitalized and lack PCR confir-
mation of infection. A key public health concern is the extent 
to which immunity in mild or asymptomatic cases may confer 
protection from future infection (6, 15–18). In this cohort 
21.5% of the 731 HCW studied had laboratory confirmed in-
fection and all were asymptomatic or had mild disease. We 
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Understanding the nature of immunity following mild/asymptomatic infection with SARS-CoV-2 is crucial 
to controlling the pandemic. We analyzed T cell and neutralizing antibody responses in 136 healthcare 
workers (HCW) 16-18 weeks after United Kingdom lockdown, 76 of whom had mild/asymptomatic SARS-
CoV-2 infection captured by serial sampling. Neutralizing antibodies (nAb) were present in 89% of 
previously infected HCW. T cell responses tended to be lower following asymptomatic infection than in 
those reporting case-definition symptoms of COVID-19, while nAb titers were maintained irrespective of 
symptoms. T cell and antibody responses were sometimes discordant. Eleven percent lacked nAb and had 
undetectable T cell responses to spike protein but had T cells reactive with other SARS-CoV-2 antigens. 
Our findings suggest that the majority of individuals with mild or asymptomatic SARS-CoV-2 infection carry 
nAb complemented by multispecific T cell responses at 16-18 weeks after mild or asymptomatic SARS-CoV-
2 infection. 
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conducted a cross-sectional case-controlled sub-study 
(n=136) to analyze T cell and nAb immunity at 16-18 weeks 
after UK lockdown (table S1). We collected samples from 76 
HCW with laboratory-defined evidence of SARS-CoV-2 infec-
tion and 60 HCW matched for age, gender and ethnicity that 
were consistently SARS-CoV-2 PCR negative and serology 
negative. Here, we set out to investigate whether asympto-
matic or mild infection with SARS-CoV-2 confers specific nAb 
and T cell responses lasting to 16-18 weeks. 
RESULTS 
SARS-CoV-2 multispecific T cell response 
A number of T cell studies investigating SARS-CoV-2 in-
fection have described the presence of Th1 immunity (7). We 
assessed SARS-CoV-2 T cell frequencies by IFNγ-ELISpot us-
ing three complementary approaches: whole protein (1), 
mapped epitope peptide (MEP) pools (4), and overlapping 
peptide (OLP) pools (3) (table S2). The use of whole protein 
allows assessment of CD4 T cell responses to naturally pro-
cessed epitopes, whereas the MEP and OLP pools assessed a 
combination of CD4 and CD8 T cell responses directed 
against defined immunogenic regions and unbiased coverage 
of key viral proteins, respectively. 
Analyzing T cell responses to spike and nucleocapsid (N) 
stimulating with whole protein in HCW with mild or asymp-
tomatic, laboratory confirmed infection, only 49% responded 
to spike whereas significantly more (85%) responded to N, 
showing a wide range of frequencies (Fig. 1A). Using MEP 
pools containing previously mapped immunogenic regions 
and offering good coverage for regional HLA genotypes (4), 
responses of >80 spot forming cells (SFC)/106 peripheral 
blood mononuclear cells (PBMC) were found in 69% to pep-
tide pools for spike, N, membrane (M) and open reading 
frame (ORF)3a/7a, with the latter being at a significantly 
lower frequency. Eighty-seven percent of HCW had detecta-
ble T cell responses to these MEP pools (Fig. 1B). A third T 
cell stimulation platform used OLP pools spanning the whole 
of N, M, and ORF3a, together with 15mers spanning immu-
nogenic regions of spike (fig. S2B); using this approach, we 
assessed multi-specificity and cumulative SARS-CoV-2-
specific T cell frequencies. This indicated a wide range of cu-
mulative T cell response frequencies, from zero to >1000 
SFC/106 PBMC, with 89% showing a detectable T cell re-
sponse (Fig. 1C). Of note with both the MEP and OLP plat-
forms, responses to ORF3a/7a or ORF3a respectively were 
significantly lower than to other antigens (Fig. 1B; fig. S1A). 
Although T cell responses to individual regions were rela-
tively weak, their cumulative frequencies across all pools 
tested were similar in magnitude to that of T cells directed 
against a pool of well-described CD8 epitopes from influenza, 
Epstein-Barr virus and cytomegalovirus (FEC), assessed in 
parallel in the same donors (fig. S1A), and comparable to 
frequencies found against SARS-CoV-1 pools following SARS 
infection (19). 
Responses to spike, N whole protein and spike, N and M 
MEP were significantly higher frequency in HCW with labor-
atory confirmed SARS-CoV-2 infection than those in the 
matched group without laboratory evidence of infection (Fig. 
1D, fig. S1, C-D). For example, 85% and 49% of HCW with la-
boratory confirmed SARS-CoV-2 had T cell responses to N 
and spike protein respectively, compared with 29% and 12% 
of SARS-CoV-2 PCR negative and S1 IgG negative HCW 
(p<0.0001) (Fig. 1D). T cell recognition of these stimuli in 
HCW without evidence of infection, irrespective of reported 
COVID-19-like symptoms, was similar to that seen in pre-
COVID-19 pandemic controls (Fig. 1D, fig. S1C, D; table S1B). 
The OLP pools (utilizing increased cell numbers) showed de-
tectable T cell responses in the PCR negative, S1 IgG negative 
HCW group (fig. S1B). With every T cell stimulation approach 
tested, responses were also seen in a proportion of pre-pan-
demic controls. Epitope mapping studies will be required to 
investigate possible cross-reactive components of these re-
sponses with other human coronaviruses as other studies 
have highlighted (2, 3, 20) and to assess the impact of any 
such cross-reactivity on disease outcome, whether positive or 
negative (21, 22). 
In addition to IFNγ SFC, we explored other cytokines in-
dicative of non-Th1 subset polarization by screening superna-
tants from spike and N protein-stimulated ELISpots; they 
showed no evidence of IL-4, 5, 13, 17 or 23 (fig. S1E). IL-2 re-
lease followed a similar pattern to that seen in the IFNγ 
ELISpots. However, TNFα was released by antigen-stimu-
lated cultures in response to N across the cohort spectrum 
from those with laboratory confirmed infection to uninfected 
HCW and pre-pandemic controls, presumably reflecting an 
amplified response from other cell types including macro-
phages and NK cells. 
In line with previous observations of SARS-CoV-2 T cells 
and aging (23), T cell responses in HCW (n=75) with labora-
tory confirmed SARS-CoV-2 correlated with age. There was a 
correlation with increasing age and T cell responses against 
spike MEP2, N1 OLP and ORF3a/7a MEP (fig. S2A-D). Broken 
down by age and gender, T cell immunity to spike increased 
with age in males (spike protein; r=0.522, p=0.006) (fig. S2E). 
We found no differences in T cell responses associated with 
ethnicity although the study was not sufficiently powered to 
report this negative finding (fig. S3A, B). T cell immunity to 
M MEP, ORF3a/7a MEP and ORF3a OLP was higher in males 
compared to females (fig. S3C, D). 
Neutralizing antibodies to SARS-CoV-2 at 16-18 weeks 
The majority of HCW in this cohort with laboratory con-
firmed SARS-CoV-2 infection had detectable S1 IgG and/or N 
IgG/IgM (97%) during follow-up; the longitudinal Ab re-
sponse to S1 and N has been reported (24). Peak antibody 
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level during 16-18-week follow-up (Fig. 2A) was considered to 
be a useful marker of humoral immune activation in each 
HCW. There have been several reports relating cohort sero-
prevalence and Ab durability by S1, RBD or N ELISA to neu-
tralizing antibodies and disease profile (1, 25–28). Some 
studies of nAb responses in severe, mild and asymptomatic 
disease have highlighted rapid waning of nAb within weeks 
(14–16, 29), with others finding a more sustained neutralizing 
response (26, 30, 31). We analyzed the nAb response in HCW 
at 16-18 weeks after UK lockdown and found that 89% could 
neutralize pseudotyped virus. There was a range of nAb titers 
detectable, with 66% having an IC50 titer of >200 (Fig. 2B, 
C); as we discuss below, there is debate as to what IC50 indi-
cates protection and we have cautiously benchmarked a cor-
relate of protection by extrapolation to viral challenge in 
macaque studies (32). Eleven percent of HCW with labora-
tory-confirmed SARS-CoV-2 infection demonstrated no de-
tectable neutralizing response (Fig. 2B, C). The eight HCW 
samples that tested negative by the pseudotyped virus neu-
tralizing assay also tested negative by the authentic SARS-
CoV-2 microneutralization assay. There was a positive corre-
lation between IC50 measurements by the pseudotyped virus 
and authentic SARS-CoV-2 microneutralization assays (fig. 
S4A, B). Typical pseudotyped virus nAb profiles in the high 
(IC50 ≥200), low (IC50 50-199) and none (IC50 ≤49) catego-
ries are shown (fig. S5A). Note that the pseudotyped virus 
nAb response positively correlated with peak S1 IgG and peak 
N IgG/IgM, in line with other reported cohorts (1, 25-27) (Fig. 
2D). Peak S1 IgG tended to be lower in those reporting non-
case defining symptoms and those who were asymptomatic 
compared to those with case-definition symptoms (Fig. 2E). 
Importantly, the nAb IC50 titer at 16-18 weeks after lockdown 
was maintained at a similar level across these three symptom 
groups (Fig. 2F). Eighty-six percent of HCW aged ≥50y devel-
oped nAb at an IC50 of >200 compared with 58% of younger 
HCW aged 24-49y; p=0.0306 (Fig. 2G). Peak S1 IgG Ab in-
creased with age in females (Fig. 2H). We looked in more de-
tail at comparative features of infected individuals in the 
HCW cohort who did or did not show a nAb response at 16-
18 weeks (fig. S5B-D); we cannot discount the possibility that 
these individuals may have shown an earlier response that 
had waned by 16-18 weeks. The 8 HCW with no nAbs spanned 
an age range of 26-53 years and tended to be at the lower end 
of the HCW age range. Although this sub-study was not pow-
ered to investigate stratified demographic differences, we 
looked at features such as gender, ethnicity, clinical role or 
location, use of personal protective equipment (PPE) or 
symptom profile and found no difference between those that 
made nAb and those that did not, though there was a trend 
to more male non-neutralizers. 
T cell and nAb responses are sometimes discordant 
To better understand complementarity between nAb and 
T cells, we next compared the T cell, S1 IgG and nAb re-
sponses in individual HCW with laboratory confirmed SARS-
CoV-2 (n=76). T cell responses to N and spike protein corre-
lated with peak S1 IgG titer, but with weak correlation coef-
ficients partly attributable to lack of T cell responses in some 
HCW with positive antibody titers to spike and N (Fig. 3A; 
blue box in fig. S6A, D). Correlations between peak N 
IgG/IgM titer and T cell responses to spike and N protein 
showed similar results (fig. S7A). Just over half of the HCW 
were discordant for T cell and S1 IgG responses, making no T 
cell response to spike protein, and 15% made no T cell re-
sponse to N (fig. S6A-F). While we found no differences in 
terms of age, gender, ethnicity, symptom profile, clinical role 
or PPE use, there tended to be more non-responders among 
Black, Asian and Minority Ethnic (BAME) HCW. There was a 
correlation between the T cell response to spike protein 
(r=0.482, p<0.0001), spike MEP (r=0.412, p<0.0001) and peak 
S1 IgG titer across all the HCW studied (those with and with-
out laboratory confirmed infection with SARS-CoV-2, n=133) 
(fig. S7B). T cell responses to spike protein (r=0.446, 
p<0.0001), spike MEP (r=0.343, p<0.0001) also correlated 
with nAb (IC50) (fig. S7B) but with some discordance. 
In Fig. 2B, we showed that 11% of infected HCW lacked 
detectable nAb at 16-18 weeks after UK lockdown. To under-
stand the complementarity between T cell and nAb responses 
in individual HCW, we analyzed responses of all HCW ranked 
either by nAb IC50 titer or cumulative T cell response. We 
first arrayed HCW responses ranked by magnitude of nAb re-
sponse (Fig. 3B). Neutralization IC50 values for all HCW were 
plotted in relation to an indicative, protective cut-off value of 
>200 (dotted horizontal red line in lower panel). HCW lack-
ing detectable nAb are indicated by 8 black arrows on the left. 
Their cumulative T cell response frequencies against viral an-
tigens are shown in the panel above and are sometimes rela-
tively low. Examining the converse, we then arrayed HCW 
responses ranked by magnitude of cumulative T cell response 
(Fig. 3C). From this plot, HCW with the lowest cumulative T 
cell response (to the left of the plot) have a range of nAb re-
sponses from none to >200 IC50. One young, asymptomatic, 
female HCW with a good peak S1 IgG titer had no T cell re-
sponse to any antigens tested but made nAbs with a titer of 
143 (Fig. 3B, C indicated by +). Another female HCW with a 
good S1 IgG titer, also had no T cell response to any antigens 
tested, but made nAbs with a titer of 747 (Fig. 3B, C indicated 
by *). 
Of the 76 HCW studied with mild or asymptomatic labor-
atory-confirmed SARS-CoV-2 infection, 64% had one or more 
case-defining symptoms, 25% had non-case-defining symp-
toms and 11% were asymptomatic. Looking at T cell immun-
ity and nAb levels across these symptom-stratified groups at 
16-18 weeks, T cell responses tended to be higher in infected 
HCW with case defined symptoms. Responses to M MEP and 
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ORF3a OLP were significantly higher in HCW reporting case 
definition symptoms than those that were asymptomatic (fig. 
S8A, B). Importantly, there was no significant fall in nAb ti-
ters across case-defining, non-case-defining symptoms and 
asymptomatic HCW groups (Fig. 3D) with 65%, 68% and 63% 
respectively showing an IC50 >200. 
Relating lack of nAbs to T cell responses to different spe-
cific antigens we show that none of the 8 HCW without de-
tectable nAb make a T cell response to spike protein (Fig. 4A). 
The addition of data from spike MEP pools (potentially en-
compassing CD8 responses as well) revealed low T cell re-
sponses to spike in 5/8 HCW lacking a nAb response (Fig. 4B). 
Exploring T cell responses to N protein and N, M, and 
ORF3a/7a MEP pools showed 6/8 HCW without detectable 
nAb making a T cell response (Fig. 4C). Furthermore, there 
were OLP T cell responses in 6/8 HCW lacking nAb (Fig. 4D). 
Thus, HCW lacking nAb tend to lack responses to spike while 
maintaining low frequency T cells to other specificities. As-
sessing T cell responses ranked simply on the basis of pres-
ence or absence of recognition of proteins and peptide pools 
(rather than magnitude of response) indicates that those 
lacking a nAb response (black arrows) showed T cell re-
sponses against 1 to 5 antigens (Fig. 4E). Taken together, the 
data show discordance of nAb and T cell responses in indi-
vidual HCW. 
We looked in more detail at the data for some of the HCW 
showing discordant elements of adaptive immunity (fig. S9). 
There was a strong correlation between nAb IC50 and con-
temporaneous Euroimmun S1 IgG titer, yet thorough scrutiny 
of the plot also revealed a significant minority of individuals 
with discordant responses (fig. S9A). This discordance be-
tween S1 binding antibody titers and neutralization, may in 
part be due conformational differences between S1 protein in 
ELISA and virally expressed S protein or to presence of neu-
tralizing antibodies targeting S2 (33, 34). Two individuals 
with laboratory confirmed SARS-CoV-2 and a positive Euro-
immun assay showed no detectable nAb response (fig. S9B, 
C). One of these showed no T cell response to spike, N protein 
or MEP, the other showed a modest T cell response. Interest-
ingly, 12 HCW with laboratory confirmed SARS-CoV-2 
showed a nAb response while also being negative for Euro-
immun S1 IgG (fig. S9B, C). Four of the 12 HCW made cumu-
lative T cell responses to spike and N protein in excess of 260 
SFC/106 and all made nAb responses of IC50 >99 and in the 
range 99 to 1184. This is an important finding since it showed 
that 12/76 (16%) HCW with proven infection with SARS-CoV-
2 who had a negative Euroimmun test at about 4 months af-
ter infection still had potentially protective nAb and/or T cell 
responses. It also showed that 2/76 (3%) HCW with proven 
infection and a positive Euroimmun antibody binding test 
had no detectable nAb response. However, the majority of 
HCW with laboratory-confirmed infection did have a 
detectable (and likely protective) level of nAbs at 16-18 weeks. 
The 11% who lack detectable nAb have fewer T cells directed 




Much debate has focused on the possibility that the Ab 
response to SARS-CoV-2 may be short-lived, while T cell 
recognition may be strong, durable, and more common (14, 
16, 17, 23, 31, 35). Mild or asymptomatic infection are very 
common but are not usually diagnosed contemporaneously, 
making assessment of the durability of immunity in this com-
mon group challenging. Here we describe a cross-sectional 
case-controlled study of an exposed HCW cohort at 16-18 
weeks after UK lockdown who had mild or asymptomatic in-
fection picked up by repeated PCR and serological testing. 
This cohort shows variable T cell responses across the viral 
proteome sampled, with only two HCW with lab-confirmed 
COVID-19 showing no detectable T cell response across all 
the platforms tested. In this study, 89% of HCW with asymp-
tomatic or mild COVID-19 had nAb at 16-18 weeks after UK 
lockdown and 66% had titers >200. In light of some reports 
of rapid waning of nAbs this result was surprising (15–17, 29). 
A limitation of our study was that (like many others), we have 
here relied on pseudotyped virus neutralization as a surro-
gate for authentic virus neutralization. Our pseudotyped vi-
rus neutralization assay has been validated in this study with 
respect to authentic SARS-CoV-2 virus neutralization and 
previously (36). However, while pseudotyped virus neutrali-
zation is valuable and shows strong correlation with live virus 
neutralization, factors such as higher spike density on the 
wild-type virion may lead to nuanced differences in sensitiv-
ity (37). Here we show a complex pattern of T cell and nAb 
responses for individual HCW. Analysis of nAbs shows that 
the majority of laboratory confirmed SARS-CoV-2 infected 
HCW with no symptoms or only mild disease had relatively 
high nAb IC50 at 16-18 weeks after UK lockdown. In the ab-
sence of any proven human correlate of protection for SARS-
CoV-2 infection, it is hard to be certain where to set the cut 
off for a ‘likely protective’ nAb IC50. The IC50s we measured 
were in the same range as those defined as conferring func-
tional protection in macaque challenge studies, but this com-
parison has the caveat that high challenge doses were used in 
those studies (32). In terms of neutralization observations in 
humans, a study of SARS-CoV-2 susceptibility during an out-
break on a fishing vessel indicated a lack of infection in those 
showing a prior nAb titer (IC50) >1/160 (38). In infection by 
SARS-CoV-1, nAbs are often lost by 1-2 years after infection 
(19, 39), whereas T cell responses can persist for up to 17y (3). 
Longitudinal follow-up of nAb versus T cell kinetics in the 
COVIDsortium cohort will illuminate T cell and nAb 
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trajectories over time. 
In terms of severe COVID-19 risk, two of the strongest fac-
tors identified have been gender and age (40). We found a 
positive correlation between peak S1 IgG Ab level and age in 
female study participants. Other observations have suggested 
a higher T cell response to mitogens in females with acute 
hospitalized COVID-19 (41); we observed higher memory T 
cell responses to spike antigen in older males. Thus, in this 
asymptomatic/mild cohort of HCW, the peak S1 IgG Ab level 
increases significantly with age in females, while it is the T 
cell response that increases significantly with age in males. 
A limitation of our study is the fact that T cell and nAb 
responses were only measured at the 16-18-week cross-sec-
tional time point. Ideally, T cell and nAb responses would be 
measured longitudinally to capture peak responses occurring 
in the period after infection and any differential decline in 
responses resulting from variations across individuals as seen 
with antibody binding responses (24). Another caveat is the 
fact that due to limitations of blood sample volume we only 
used one detection system to measure T cell responses, the 
IFNγ ELISpot. Other labs have opted to elicit low frequency 
responses by prior expansion in peptides with IL-2. We con-
sidered that such expansion might obviate our ability to draw 
direct conclusions about response frequencies. 
A cautionary note about the ephemeral nature of adaptive 
immunity to coronaviruses comes from data for annual rein-
fections with the four seasonal coronaviruses and emerging 
data for reinfection by SARS-CoV-2 (42, 43). Some studies 
have raised concern about the durability of serum antibodies 
and B cell memory, with data pointing toward impaired ger-
minal center reactions in severe acute COVID-19 (35). Other 
studies have focused on the potential for rapid waning of nAb 
after mild SARS-CoV-2 infection (14, 15). However, we find 
nAb detectable in the majority of HCW sampled 16-18 weeks 
after mild/asymptomatic infection. Some T cell data indicates 
that even asymptomatic people and household contacts de-
velop low-frequency T cell responses, in line with results from 
the HCW without laboratory confirmed infection using one 
of our platforms with higher T cell numbers (6). We show 
here that infected HCW can display highly heterogeneous T 
cell recognition of epitopes from diverse SARS-CoV-2 struc-
tural and non-structural proteins, but it is not yet possible to 
decode the differential impacts of these responses for protec-
tion. Analysis of T cell response repertoire in convalescent, 
hospitalized COVID-19 patients argues that breadth of T cell 
response is a marker of mild disease (44). 
While Ab and/or T cell data have been reported in several 
settings (1–8, 13–16, 23–31), many studies lack the granularity 
to relate binding Ab, nAb, and broad-range T cell response 
analysis to long-term immunity after asymptomatic or mild 
disease – the common COVID-19 experience of the majority 
of individuals. Our cohort study highlights the heterogeneity 
of immune memory in exposed individuals with mild or 
asymptomatic infection, cautioning against simple assertions 
about ‘typical’ responses in most people. The cohort shows 
discordance between nAb and T cell responses with some in-
dividuals showing good nAb responses alongside low T cell 
responses and vice versa. When T cell responses are present, 
they are of variable frequency and specificity. There are also 
HCW lacking evidence of seroreactivity by S1 Euroimmun as-
say, yet with evidence of a positive neutralizing antibody re-
sponse. While we find relative discordance of responses in 
our study comprising individuals at 4 months after infection, 
other reports of concordance either between S1 Ab and neu-
tralization or between neutralization and spike CD4 T cell re-
sponses tended to analyze within the first weeks after 
infection (2, 45). 
In summary, we find that in the majority of these working 
adults there is immunity at 16-18 weeks comprising nAb (of-
ten at a level likely to protect), usually complemented by 
multi-specific T cell responses. Understanding protective im-
munity in the population will require simultaneous scrutiny 
of T cell and antibody responses. 
MATERIALS AND METHODS 
Study design 
We conducted a cross-sectional case-controlled sub-study 
of 136 hospital based HCW at 16-18 weeks after UK lockdown 
(Fig. 5). Seventy-six HCW with mild/asymptomatic laboratory 
confirmed SARS-CoV-2 infection captured by weekly SARS-
CoV-2 PCR and Euroimmun/Roche antibody tests were re-
cruited. An age, sex, symptom and ethnically matched group 
of 60 HCW with similar exposure that remained SARS-CoV-2 
PCR negative and Euroimmun/Roche antibody test negative 
throughout the 16-week follow up period were also recruited. 
The HCW completed a symptom diary and were divided into 
those that reported one or more case definition symptoms, 
non-case definition symptoms or were asymptomatic during 
the 16-week follow up period and in the 3 months prior to the 
start of the study. The main objective of the study was to in-
vestigate T cell and neutralizing antibody immunity to SARS-
CoV-2 infection in asymptomatic/mild COVID-19 in a work-
ing adult cohort. 
Ethics statement 
The COVIDsortium Healthcare Workers bioresource was 
approved by the ethical committee of UK National Research 
Ethics Service (20/SC/0149) and registered on ClinicalTri-
als.gov (NCT04318314). The study conformed to the princi-
ples of the Helsinki Declaration, and all subjects gave written 
informed consent. 
Pre-pandemic healthy donor samples were collected and 
cryopreserved before October 2019 (table S2). Pre-pandemic 
cohort A and B samples were recruited under ethics numbers 
17/LO/0800 and 11/LO/0421 respectively. 
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COVIDsortium Healthcare Worker Participants 
Adult HCW (>18 years old) from a range of clinical set-
tings who self-declared as fit to attend work were invited to 
participate via local advertisement of the project (see 
https://covid-consortium.com). Full study details of the bio-
resource (participant screening, study design, sample collec-
tion, and sample processing) have been previously published 
(10). 
A cohort of 400 HCW was initially recruited from St Bar-
tholomew’s Hospital, London, in the week of UK lockdown 
(23rd-31st March 2020). All participants were asymptomatic 
and self-declared fit to attend work in hospital. Recruitment 
was extended (27th April-7th May 2020) to include 331 addi-
tional participants from multiple sites: St Bartholomew’s 
Hospital (n=101 additional), NHS Nightingale Hospital 
(n=10), and Royal Free NHS Hospital Trust (n=220). 
A prospective, observational, longitudinal cohort design 
was used and consisted of questionnaires exploring demo-
graphic, clinical and exposure risks, and sample collection at 
baseline and weekly follow-up for 15w from the start of each 
cohort. Participants were asked to provide details and timing 
of symptoms in the 3 months prior to baseline, and for those 
who were unable to attend follow-up visits (due to shift ros-
tering, annual leave or self-isolation), the reason for non-at-
tendance was collected, to ensure capture of information 
regarding isolation due to participant symptoms or house-
hold contacts. On return from self-isolation with symptoms, 
convalescent samples were collected. Further follow-ups at 6 
and 12 months are planned. 
Complete details of the sampling protocol have been pre-
viously published (10). Initial analysis of samples for deter-
mining infection with SARS-CoV-2 included: nasal RNA 
stabilizing swabs baseline and weekly with reverse transcrip-
tase polymerase chain reaction (RT-PCR): Roche cobas® 
SARS-CoV-2 test; Ab testing baseline and weekly: IgG Ab as-
say to spike protein S1 antigen, (EUROIMMUN Anti-SARS-
CoV-2 enzyme-linked immunosorbent assay [ELISA]); and 
anti-nucleocapsid total antibody assay (ROCHE Elecsys Anti-
SARS-CoV-2 electrochemiluminescence immunoassay 
[ECLIA]). Antibody ratios > 1.1 were considered test positive 
for the EUROIMMUN SARS-CoV-2 ELISA and >1 was consid-
ered test positive for the ROCHE Elecsys anti-SARS-CoV-2 
ECLIA following published Public Health England (PHE) 
evaluations (46, 47). 
At baseline, information relating to demographics and ex-
posures was collected via a standardized questionnaire. Mean 
age of the cohort (n=731) was 38 ± 11 years; 33% are male, 
31% nurses, 20% doctors, and 19% work in intensive care 
units. COVID-19-associated risk factors were: 37% Black, 
Asian or minority ethnicities (BAME); 18% smokers; 13% obe-
sity; 11% asthma; 7% hypertension and 2% diabetes mellitus 
(10). At weekly follow-up visits information relating to 
symptom burden was recorded using a standardized ques-
tionnaire. Symptoms were classified as follows: ‘case-defin-
ing’ (fever, new continuous dry cough or a new loss of taste 
or smell), ‘non-case-defining’ (specific symptoms other than 
case-defining symptoms, or unspecified symptoms), or 
asymptomatic (no symptoms reported). 
Case definition for coronavirus disease 2019 (COVID-19), 
as of 29 May 2020 European Centre for Disease Prevention 
and Control [https://www.ecdc.europa.eu/en/covid-
19/surveillance/case-definition] 
A total of 731 HCW underwent 16 weeks of serial assess-
ment (attending unless ill, self-isolating, on holiday, or rede-
ployed). Across the main study cohort, 48 participants had 
positive RT-PCR results with 157 (21.5%) seropositive partici-
pants. Infections were asymptomatic or mild with only two 
hospital admissions (neither requiring intensive care admis-
sion, both discharged well). The cohort therefore represents 
working age community COVID-19 rather than hospitalized 
COVID-19. 
In London, the case-doubling time in March, 2020 was ap-
proximately 3–4 days. The number of nasal swabs testing pos-
itive for SARS-CoV-2 in our study peaked at March 23rd to 
31st, 2020 suggesting that infections peaked on or around 
March 23rd, 2020, the day of UK lockdown. We thus observed 
approximately synchronous infections coincident with the 
peak epidemic transmission in London at the start of the 
study, UK lockdown on March 23rd and therefore used this as 
the benchmark starting point for our analysis of T cell and 
nAb responses in the first wave (24). 
The cross-sectional case controlled sub-study (n=136) col-
lected samples at 16-18 weeks after UK lockdown (Table S1, 
Fig. 5). The cross-sectional case controlled sub-study included 
76 HCW (mean age 41y, 36% male) with laboratory defined 
evidence of SARS-CoV-2 either by SARS-CoV-2 positive PCR 
and/or positive for spike IgG (Euroimmun ELISA)/ N 
IgG/IgM antibody (Roche Elecsys). Fifty-seven percent re-
ported one or more case defining COVID-19 symptoms. 
Twenty-four percent reported non-case defining symptoms 
and 19% were asymptomatic at baseline, during 16-week fol-
low-up or in the 3 months prior to baseline. A second age, 
gender, and ethnicity matched subgroup of sixty HCW were 
recruited (mean age 39y, 37% male) who were SARS-CoV-2 
PCR negative and negative for spike IgG (Euroimmun ELISA) 
and N IgG/IgM antibody (Roche Elecsys) tests throughout 
the 16-week follow-up. However, forty-four percent reported 
one or more case defining COVID-19 symptoms, 41% non-case 
defining symptoms and 15% were asymptomatic at baseline, 
during 16-week follow-up and in the 3 months prior to base-
line. There was no significant difference in T cell or nAb re-
sponses measured in HCW with laboratory confirmed SARS-
CoV-2 that were recruited into the parent study via cohort 1 
or 2 (fig. S10). 
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Isolation of PBMC 
Peripheral blood mononuclear cells (PBMC) were isolated 
from heparinized blood samples using Pancoll (Pan Biotech) 
or Histopaque®-1077 Hybri-MaxTM (Sigma-Aldrich) density 
gradient centrifugation in SepMate tubes (StemCell) accord-
ing to the manufacturer’s specifications. Isolated PBMCs 
were cryopreserved in fetal calf serum containing 10% DMSO 
and stored in liquid nitrogen. 
Isolation of serum 
Whole blood samples were collected in SST vacutainers 
(VACUETTE® #455092) with inert polymer gel for serum sep-
aration and clot activator coating. After centrifugation at 
1000 X g for 10 min at room temperature, serum layer was 
aliquoted and stored at -800C for specific SARS-CoV-2 Ab titer 
detection by ELISA and for SARS-CoV-2 spike pseudotyped 
virus neutralization assays. 
SARS-CoV-2 specific Ab titer 
SARS-CoV-2 antibody testing was carried out in the labor-
atories of Public Health England UK using two commercial 
assays following the manufacturers’ instructions. The Euro-
immun anti-SARS-CoV-2 enzyme-linked immunosorbent as-
say (ELISA) (IgG) measures serum IgG against SARS-CoV-1 
S1 antigen (46) and the Roche Elecsys Anti-SARS-CoV-2 elec-
trochemiluminescence immunoassay (ECLIA) measures se-
rum antibody (including IgG) directed against the SARS-CoV-
2 N (47). The Euroimmun ELISA was carried out using a 
Stratec Gemini automated microplate processor. Raw optical 
density OD 450nm readings were adjusted by calculating the 
ratio of the OD of control or participant sample divided by 
the calibrator OD. A ratio of ≥ 1.1 was deemed positive. A ratio 
of 11 was taken to be the upper threshold as the assay satu-
rates beyond this point. The Roche ECLIA was performed us-
ing a Roche Cobas® e801 Immunoassay Analyzer. Results 
were expressed as a cut-off index (COI) calculated by the an-
alyzer software as the electrochemiluminescence signal ob-
tained from the participant sample divided by the lot-specific 
cut-off value. A COI value ≥ 1 was deemed positive. Across 
their dynamic range, the semiquantitative indices of both as-
says approximate to a linear relationship with antibody level 
(24). 
Recombinant proteins 
The SARS-CoV-2 S1 spike antigen and nucleocapsid pro-
teins were obtained from the Centre for AIDS Reagents 
(CFAR), National Institute for Biological Standards and Con-
trol (NIBSC), UK and consisted of SARS-CoV-2 nucleoprotein 
and S1 spike antigen from Dr. Peter Cherepanov, Francis 
Crick Institute, UK. 
Mapped epitope pools (MEP) 
Pools of 13-20mer peptides based on the protein se-
quences of SARS-CoV-2 S1 (spike), nucleocapsid (N), mem-
brane (M) and open reading frames 3a and 7a (ORF3a/7a) 
described previously were synthesized (4) (GL Biochem 
Shanghai Ltd, China). To stimulate PBMC, separate pools of 
sequences for Spike (18 peptides), N (10 peptides), M (6 pep-
tides) and ORF3a/7a (7 peptides) were used (table S2). A sec-
ond mapped epitope pool of SARS-CoV-2 S1 peptides (spike 
MEP2) based on alignment of all sequences of published 
SARS-CoV-1 epitopes (www.iedb.org; search criteria: positive 
assays only, T cells assays, host: human) with the spike-SARS-
CoV-2 sequence and 15-mer peptides synthesized to cover the 
homologous sequences. In addition, we synthesized 15-mer 
peptides covering the predicted SARS-CoV-2 spike epitopes 
(3) to give a total of 55 peptides in this pool (Spike MEP2) 
(table S2) 
Overlapping peptide pools (OLP) 
15-mer peptides overlapping by 10 amino acids spanning 
the entire protein sequence of SARS-CoV-2 nucleocapsid (N), 
Membrane (M) and ORF3a were synthesized (GL Biochem 
Shanghai Ltd) (Table 2). To stimulate PBMC, the peptides 
were divided into 4 pools covering N (N1, N2, 41 peptides 
each), M (43 peptides), and ORF3a (53 peptides). 
IFNγ-ELISpot Assay 
Unless otherwise stated, culture medium for human T 
cells was sterile 0.22μM filtered RPMI medium (GibcoBRL) 
supplemented with 10% by volume heat inactivated (1h, 
64°C) fetal calf serum (FCS; Hyclone, and 1% by volume 100x 
penicillin and streptomycin solution (GibcoBRL). 
For experiments involving T cell stimulation with proteins 
or MEP peptide pools, pre-coated ELISpot plates (Mabtech 
3420-2APT) were washed x4 with sterile PBS and were 
blocked with R10 for 1h at room temperature. 200,000 PBMC 
were seeded in R10/well and were stimulated for 18-22h at 
37°C with 5%CO2 with SARS-CoV-2 recombinant proteins 
(10μg/ml) or MEP pools (10μg/ml/peptide). Internal plate 
controls were R10 alone (without cells) and anti-CD3 
(Mabtech mAb CD3-2). At the end of the stimulation period, 
cell culture supernatants were collected and stored for later 
cytokine analysis by Luminex and ELISA. ELISpot plates 
were developed with human biotinylated IFNγ detection Ab, 
directly conjugated to alkaline phosphatase (7-B6-1-ALP, 
Mabtech; 1μg/ml), diluted in PBS with 0.5% FCS, incubating 
100μl/well for 2h at room temperature. This was followed by 
100μl/well of sterile filtered BCIP/NBT-plus Phosphatase 
Substrate (Mabtech) for 5 min at room temperature. Plates 
were washed in ddH20 and left to dry completely before be-
ing read on AID-ELISpot plate reader. For experiments in-
volving T cell stimulation with OLP peptide pools and spike 
MEP2 pool ELISpot plates (Merck-Millipore, MSIP4510) were 
coated with human anti-IFNγ Ab (1-D1K, Mabtech; 10μg/ml) 
in PBS overnight at 4°C. Plates were washed x6 with sterile 
PBS and were blocked with R10 for 2h at 37°C with 5% CO2. 
PBMC were thawed and rested in R10 for 3h at 37°C with 5% 
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CO2 before being counted. 400,000 PBMC were seeded in 
R10/well and were stimulated for 16-20h with SARS-CoV-2 
OLP pools or spike MEP2 pool (2μg/ml/peptide). Internal 
plate controls were R10 alone (without cells) and two DMSO 
wells (negative controls), concanavalin A (ConA, positive con-
trol; Sigma-Aldrich) and FEC (HLAI-restricted peptides from 
influenza, Epstein-Barr virus, and CMV; 1μg/ml/peptide). 
ELISpot plates were developed with human biotinylated IFN-
γ detection antibody (7-B6-1, Mabtech; 1μg/ml) for 3h at 
room temperature, followed by incubation with goat anti-bi-
otin alkaline phosphatase (Vector Laboratories; 1:1000) for 
2h at room temperature, both diluted in PBS with 0.5% BSA 
by volume (Sigma-Aldrich), and finally with 50μl/well of ster-
ile filtered BCIP/NBT Phosphatase Substrate (ThermoFisher) 
for 7 min at room temperature. Plates were washed in ddH20 
and left to dry overnight before being read on an AID classic 
ELISpot plate reader (Autoimmun Diagnostika GMBH, Ger-
many). 
Analysis of ELISpot data was performed in Microsoft Ex-
cel. The average of two R10 alone wells or DMSO (Sigma-Al-
drich) wells was subtracted from all peptide stimulated wells 
and any response that was lower in magnitude than 2 stand-
ard deviations of the sample specific control wells was not 
considered a peptide specific response. Results were ex-
pressed as difference in (delta) spot forming cells per 106 
PBMC between the negative control and protein/peptide 
stimulation conditions. We excluded the results if negative 
control wells had >100 SFU/106 PBMC or positive control 
wells (ConA or anti-CD3) were negative. Results were plotted 
using Prism v. 7.0e and 8.0 for Mac OS (GraphPad). 
Cytokine measurement 
Concentrations of IL-2 and TNF  in cell culture superna-
tants in response to PBMC stimulation with spike or N pro-
tein were measured by ELISA using Duo-set® antibody pairs 
and standards (Bio-Techne). Optical density measurements 
were performed on a FLUOstar Omega Microplate reader 
(BMG Labtech). Concentrations of IL-4, IL-5, IL-13, IL-17a 
and IL-23 were measured by multiplex Luminex® assay (Bio-
Techne) on a Bio-Plex 200 instrument (Bio-Rad Laboratories, 
Ltd). Cytokine levels were calculated in Microsoft Excel and 
concentrations for protein stimulated samples obtained by 
subtracting values for media only controls. Standard curves 
were plotted using Prism 8.0 for Mac OS (GraphPad). 
Cell Lines 
HEK-293T and Huh7 (both ATCC) were cultured and 
maintained in high glucose Dulbecco’s Modified Eagle’s Me-
dium and supplemented with GlutaMAX, 10% (v/v) heat-in-
activated fetal bovine serum (FBS, 56°C for 30 min), 
100IU/ml penicillin and 100μg/ml streptomycin. Cell lines 
were cultured at 37°C with 5% CO2. 
 
Production and titration of SARS-CoV-2 pseudotyped 
lentiviral reporter particles 
Pseudotype stocks were prepared by linear polyethyl-
enimine 25K (Polysciences) co-transfection of HEK-293T 
(ATCC) with SARS-CoV-2 spike pcDNA expression plasmid, 
HIV gag-pol p8.91 plasmid and firefly luciferase expressing 
plasmid pCSFLW at a 1:1:1.5 ratio (47, 48). 2.5x104 cells/cm2 
were plated 24h prior to transfection in 60cm2 cell culture 
dishes. 48 and 72h post transfection, pseudotype-containing 
culture medium was harvested and centrifuged at 500xg for 
5 min to clear cell debris. Aliquots were stored at -80°C. TCID 
assays were performed by transduction of Huh7 cells to cal-
culate the viral titer and infectious dose for neutralization as-
says. p24 ELISA was also used to determine input 
concentration. 
p24 ELISA 
Pseudotype stock concentrations were determined by 
ELISA for p24 protein concentration as previously described 
(49). White ELISA plates were pre-coated with 5μg/ml sheep 
anti-HIV-1 p24 antibody (Aalto Bio Reagents) at 4°C over-
night. Pseudoviral supernatants were treated with 1% Empi-
gen BB (Merck) for 30 min at 56°C and then plated at 1:10 
dilution in Tris-buffered saline (TBS) on pre-coated plates 
and incubated for 3h at room temperature. Alkaline phospha-
tase-conjugated mouse anti-HIV-1 p24 monoclonal antibody 
(Aalto Bio Reagents) in TBS, 20% (v/v) sheep serum, 0.05% 
(v/v) Tween 20 was then added and incubated for 1h at room 
temperature. After 4 washes with phosphate-buffered saline 
(PBS)-0.01% (v/v) Tween 20 and 2 washes with ELISA Light 
washing buffer (ThermoFisher), CSPD substrate with Sap-
phire II enhancer (ThermoFisher) was added and incubated 
for 30 min at room temperature before chemiluminescence 
detection using a CLARIOStar Plate Reader (BMG Labtech). 
Pseudotyped SARS-CoV-2 neutralization assays 
SARS-CoV-2 pseudotype neutralization assays were con-
ducted using pseudotyped lentiviral particles as previously 
described (48–51). The pseudotype virus assay used here was 
developed, characterized and validated relative to live virus 
by ourselves and one of the authors previously (36). Serum 
was heat-inactivated at 56°C for 30 min to remove comple-
ment activity. Serum dilutions in DMEM were performed in 
duplicate in white, flat-bottom 96-well plates (ThermoFisher, 
#136101) with a starting dilution of 1 in 20 and 7 consecutive 
2-fold dilutions to a final dilution of 1/2,560 in a total volume 
of 100μl. 1 x105 RLU of SARS-CoV-2 pseudotyped lentiviral 
particles were added to each well and incubated at 37°C for 
1h. 8 control wells per plate received pseudotype and cells 
only (virus control) and another 8 wells received cells only 
(background control). Negative controls of pooled pre-pan-
demic sera, collected prior to 2008, and a positive neutralizer 
were spaced throughout the plates. RLUs for each well were 
standardized against technical positive (virus control) and 
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negative (cells only) controls on each plate to determine a 
percentage neutralization value. 4x104 Huh7 cells suspended 
in 100μl complete media were added per well and incubated 
for 72h at 37°C and 5% CO2. Firefly luciferase activity (lumi-
nescence) was measured using Steady-Glo® Luciferase Assay 
System (Promega) and a CLARIOStar Plate Reader (BMG 
Labtech). An average neutralization was calculated across 
two sample replicates for each serum dilution. Neutralization 
curves for each serum sample were plotted and the percent-
age neutralization modeled as a logistic function of the serum 
dilution factor (log10). Representative neutralization curves 
for ‘High’, ‘Low’ and ‘None’ neutralizers are shown in Fig. 
S5A. A non-linear regression (curve fit) method was used to 
determine the dilution fold that neutralized 50% (IC50). A re-
sult of IC50 greater than 49 was deemed positive. 
Authentic SARS-CoV-2 and titration 
SARS-CoV‐2 strain 2019‐nCoV/BavPat1/2020 authentic 
virus cell culture supernatant (isolate collection date 1st Jan-
uary 2020) was purchased from the European Virus Archive 
Global (EVAg, Charité Universitätsmedizin Berlin, Germany). 
VeroE6 were seeded in 75cm2 cell culture flasks 24h before 
inoculation with virus cell culture supernatant containing 2.2 
× 106 PFU in a volume of 10ml DMEM 10% FBS. Flasks were 
observed daily and virus-containing cell culture medium was 
harvested when >80% of cells showed cytopathic effect (CPE). 
Supernatant was centrifuged at 500 × g for 5 min to clear cell 
debris and aliquots stored at -80°C. 
To determine the titer of SARS-CoV-2 virus stocks, VeroE6 
cells were seeded at 3 × 104 cells per well in 48-well plates. 
After 24h, adherent cell monolayers were challenged with se-
rial 1 in 10 duplicate dilutions of virus and titer was assessed 
after 20h by in situ intracellular staining to identify foci of 
infection. Cells were washed in PBS, fixed in ice-cold metha-
nol:acetone (50:50) and virus antigen was stained using sera 
from convalescent individuals diluted 1 in 2000 in PBS 1% 
FCS for 1h at 37°C. Cells were washed a further 3 times in PBS 
and incubated with goat anti-human IgG β-galactosidase-
conjugated antibody (#2040-06, Southern Biotech) diluted 1 
in 400 in PBS 1% FCS for 1h at 37°C. After 3 further PBS 
washes, 300μl of 0.5mg/ml 5-bromo-4-chloro-3-indolyl ß-D-
galactopyranoside chromogenic substrate (X-gal) in PBS con-
taining 3 mM potassium ferricyanide, 3 mM potassium ferro-
cyanide and 1 mM magnesium chloride was added to each 
well. Infected cells incubated at 37°C stained blue within 1 
and 4h after addition of substrate and clusters of blue cells 
were counted as foci of infection to determine the virus titer 
defined as focus forming units (FFU) per ml. 
Authentic SARS-CoV-2 microneutralization assays 
VeroE6 cells were seeded at 2 × 104 cells per well in a clear, 
flat-bottom 96-well tissue culture plate 24h before infection. 
Participant serum was heat-inactivated for 30 min at 56°C to 
remove complement activity. Serum dilutions in DMEM were 
performed in duplicate in clear u-bottom 96 well plates with 
a starting dilution of 1 in 20 and 7 consecutive 2-fold dilutions 
to a final dilution of 1/2,560 in a total volume of 50μl per well. 
3 × 104 FFU of SARS-CoV-2 virus were added to each serum 
dilution and incubated at 37°C for 1h. After incubation, se-
rum/virus preparations were transferred into cell culture 
plates containing semi-confluent VeroE6 monolayers. Each 
plate had 8 control wells with virus and cells only (virus con-
trol) and another 8 wells with cells only (background only). 
Plates were incubated (37°C and 5% CO2) for 72h, after which 
supernatants were removed and wells washed with PBS. Cells 
were fixed with 100 μl 3.7% (vol/vol) formaldehyde for 1h. Af-
ter two further PBS washes, cells were stained with 0.2% 
(wt/vol) crystal violet solution for 10 min. Plates were washed 
four times in distilled water to remove excess crystal violet 
and left to air dry. Crystal violet stain was re-solubilized by 
addition of 100μl 1% (wt/vol) sodium dodecyl sulfate solution 
to each well and incubated at 37°C for 10 min. Absorbance 
readings were taken at 570nm using a CLARIOStar Plate 
Reader (BMG Labtech). Negative controls of pooled pre-pan-
demic sera, collected prior to 2008, and serum from a neu-
tralization positive SARS-CoV-2 convalescent individual were 
spaced throughout the plates. Absorbance readings for each 
well were standardized against technical positive (virus con-
trol) and negative (cells only) controls on each plate to deter-
mine a percentage neutralization value. An average 
neutralization was calculated across the two sample repli-
cates for each serum dilution. Neutralization curves for each 
serum tested were plotted, with the percentage neutraliza-
tion modeled as a logistic function of the serum dilution fac-
tor (log10). A non-linear regression (curve fit) method was 
used to determine the dilution fold that neutralized 50% 
(IC50). We classified positive samples as those with an IC50 
greater than 49. SARS-CoV-2 is classified as a hazard group 3 
pathogen and therefore all authentic SARS-CoV-2 propaga-
tion and microneutralization assays were performed in a con-
tainment level 3 facility. 
Statistics and reproducibility 
Data was assumed to have a non-Gaussian distribution. 
Nonparametric tests were used throughout. For single paired 
and unpaired comparisons Wilcoxon matched-pairs signed 
rank test and a Mann-Whitney U test were used. For multiple 
paired and unpaired comparisons Friedman multiple com-
parisons ANOVA with Dunn's correction or Kruskal-Wallis 
one-way ANOVA with Dunn’s correction were used. For cor-
relations, Spearman’s r test was used. A p value <0.05 was 
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Fig. 1. T cell responses to SARS-CoV-2 antigens in HCW (laboratory-confirmed COVID-19) at 16-18 weeks after 
UK lockdown. (A-C) Magnitude of T cell response and proportion of HCW with a summed T cell response within
the given ranges (0, 1-19, 20-79, ≥80 ΔSFC/106 PBMC). (A) Spike and N protein (n =75), (B) mapped epitope 
peptide (MEP; n = 75) and (C) overlapping peptide (OLP) pools (n =71, ordered by cumulative magnitude) in HCW
with laboratory-confirmed SARS-CoV-2 infection (n = 75). (D) Proportion of HCW with a T cell response to SARS-
CoV-2 individual proteins or peptide pools within given ranges (0, 1-19, 20-79, ≥80 ΔSFC/106 PBMC) in the 
following groups: HCW cohort with laboratory-confirmed infection (n = 75); HCW cohort with no laboratory-
confirmed infection but with one or more case-definition symptoms (n = 26), non-case-definition symptoms (n = 
24) or asymptomatic (n = 9); pre-COVID-19 pandemic control cohort A (n = 20). (A-B) Bars at geomean. (A) 
Wilcoxon matched-pairs signed rank test. (B) Friedman multiple comparisons ANOVA with Dunn’s correction. Ab,
antibody; HCW, health care workers; M, Membrane; ORF, open reading frame; N, nucleocapsid; S1, spike subunit
1; SFC, spot forming cells per 106 PBMC. 
 













Fig. 2. nAb responses to SARS-CoV-2 antigens in HCW (laboratory-confirmed COVID-19) at 16-18 weeks after UK 
lockdown. (A) Peak S1 IgG antibody titer and peak N IgG/IgM Ab titer across the study period in HCW with laboratory-
confirmed SARS-CoV-2 infection (n = 76). (B) The distribution of nAb (IC50) titers across the cohort of HCW with 
laboratory-confirmed infection and (C) The proportion of HCW with an undetectable (0-49), low (50-199) or high 
(200+) nAb titer (IC50). (D) Correlation between peak S1 IgG Ab titer (left) or the peak N IgG/IgM Ab titer (right) and 
nAb titer (IC50) in HCW with laboratory-confirmed SARS-CoV-2 infection. (E-F) Peak S1 IgG Ab titer (E) and nAb titer 
(IC50) (F) in HCW with laboratory-confirmed infection, stratified by symptom group: ≥1 COVID-19 case-definition 
symptoms (Red), non-case definition symptoms (Blue) or asymptomatic (Grey) throughout trial and within 3-months 
of trial initiation. (G) The proportion of HCW with an undetectable (0-49), low (50-199) or high (200+) nAb titer (IC50) 
within specified age ranges; 20-29 years (n = 13), 30-39 years (n = 26), 40-49 years (n = 16) and ≥50 years (n = 21). 
(H) Correlations of age vs. peak S1 IgG Ab titer (left) and neutralizing antibody titer (IC50; right) in HCW with 
laboratory-confirmed SARS-CoV-2 infection separated by gender (female, black symbols; male, open symbols). (D, 
H) Spearman’s rank correlation, least squares log-log lines shown. (A-B, E-F) bars at geomean. (E, F) Kruskal Wallis 
multiple comparison ANOVA with Dunn’s correction, not significant. Ab, antibody; N, nucleocapsid; nAb, neutralizing 
antibody; S1, spike subunit 1; SFC, spot forming cells per 106 PBMC; Y, years. 
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Fig. 3. Concordant and discordant T cell and nAb responses in HCW (laboratory-confirmed COVID-19) at 16-18 
weeks after UK lockdown. (A) Correlations between the peak S1 IgG Ab titer and T cell responses to spike protein (left) 
or N protein (right) in HCW with laboratory-confirmed SARS-CoV-2 infection (n = 75). (B) Top panel; Cumulative 
magnitude of the T cell response to spike and N proteins, mapped epitope peptide (MEP and MEP2) panels and
overlapping peptide (OLP) panels (top panel) ordered by increasing magnitude of nAb response (bottom panel) or (C) 
Magnitude of nAb response (top panel) ordered by increasing cumulative magnitude of T cell response to spike and N
proteins, MEP/MEP2 panels and OLP panels (bottom panel) in HCW with laboratory-confirmed SARS-CoV-2 infection 
(n = 70). HCW with no nAb (IC50 titer less than 50) are indicated by black arrows. + and * denote individuals with no T
cell response to any protein or peptide pool. (D) Proportion of HCW with a nAb titer (IC50) or T cell response to spike
and N proteins within given ranges stratified by symptom group; ≥1 COVID-19 case definition symptoms (n = 49 or 48), 
non-case definition symptoms (n = 19) or asymptomatic (n = 8) (A) Spearman’s rank correlation. HCW, health care 
workers; M, Membrane; ORF, open reading frame; N, nucleocapsid; nAb, neutralizing antibody; S1, spike subunit 1; SFC,
spot forming cells per 106 PBMC. 
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Fig. 4. Discordant T cell and nAb responses broken down by 
T cell antigen. (A-D) Top panels; Magnitude of the T cell 
response to spike protein (n = 75) (A) Cumulative magnitude of 
T cell responses to spike protein and spike mapped epitope
peptide (MEP and MEP2) pools (n = 70) (B) N protein and N, M 
and ORF3a/7a MEP pools (n = 75) (C) or N1, N2, M and ORF3a 
overlapping peptide (OLP) pools (n = 70) (D) ordered by 
increasing cumulative magnitude of T cell responses in HCW
with laboratory-confirmed SARS-CoV-2 infection. Bottom 
panels; nAb titers (IC50) in HCW with laboratory-confirmed 
SARS-CoV-2 infection, ordered by corresponding top panel. (E) 
The number of reactive SARS-CoV-2 proteins or peptide pools 
(top panel) and nAb titer (IC50; bottom panel) in HCW with
laboratory-confirmed SARS-CoV-2 infection (n = 70). Top panel 
ordered by cumulative magnitude; bottom panel ordered by top
panel. HCW with no nAb (IC50 titer less than 50) are indicated
by black arrows. + and * denote two individuals with no T cell
response to any protein or peptide pool. HCW, healthcare
workers; M, Membrane; N, nucleocapsid; nAb, neutralizing
antibody; ORF, open reading frame; SFC, spot forming cells per
106 PBMC. 















Fig. 5. CONSORT flow diagram for the COVIDsortium London healthcare worker cohort and sub-cohort. 
CONSORT flow diagram showing participant recruitment into COVIDsortium London healthcare worker
parent study and sub-study. Participants were stratified by SARS-CoV-2 PCR and antibody laboratory tests 
and by symptoms experienced during 16 weeks follow-up and in the 3 months prior to study initiation. SARS-
CoV-2 laboratory test positive and negative participant sub-cohort groups were matched for gender, age and 
ethnicity. 
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